Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-7 (rhBMP-7/rhOP-1): histological observations

作者：Susin Cristiano^*; Qahash Mohammed; Polimeni Giuseppe; Lu Ping Hung; Prasad Hari S; Rohrer Michael D; Hall Jan; Wikesjoe Ulf M E

来源：Journal of Clinical Periodontology, 2010, 37(6): 574-581.

DOI：10.1111/j.1600-051X.2010.01554.x

• alveolar augmentation
• bone morphogenetic protein
• dental
• oral implants
• dogs
• osseointegration
• rhBMP-7
• rhOP-1
• seroma
• tissue engineering
• titanium
• titanium porous oxide

P>Background
Pre-clinical studies have shown that recombinant human bone morphogenetic protein-2 (rhBMP-2) coated onto purpose-designed titanium porous-oxide surface implants induces clinically relevant bone formation and osseointegration. The objective of this study was to examine the potential of rhBMP-7, also known as recombinant human osteogenic protein-1 (rhOP-1), coated onto titanium porous-oxide surface implants to support vertical alveolar ridge augmentation and implant osseointegration.
Materials and Methods
Bilateral, critical-size, 5 mm, supraalveolar peri-implant defects were created in six young adult Hound Labrador mongrel dogs. The animals received implants coated with rhBMP-7 at 1.5 or 3.0 mg/ml randomized to contra-lateral jaw quadrants. The mucoperiosteal flaps were advanced, adapted, and sutured to submerge the implants for primary intention healing. The animals received fluorescent bone markers at 3, 4, 7, and 8 weeks post-surgery when they were euthanized for histological evaluation.
Results
Without striking differences between treatments, the implant sites exhibited a swelling that gradually regressed to become hard to palpation disguising the implant contours. The histological evaluation showed robust bone formation; the newly formed bone assuming characteristics of the contiguous resident bone, bone formation (height and area) averaging 4.1 +/- 1.0 versus 3.6 +/- 1.7 mm and 3.6 +/- 1.9 versus 3.1 +/- 1.8 mm2; and bone density 56% versus 50% for implants coated with rhBMP-7 at 1.5 and 3.0 mg/ml, respectively. Both treatments exhibited clinically relevant osseointegration, the corresponding bone-implant contact values averaging 51% and 47%. Notable peri-implant resident bone remodelling was observed for implants coated with rhBMP-7 at 3.0 mg/ml.
Conclusions
rhBMP-7 coated onto titanium porous-oxide surface implants induces clinically relevant local bone formation including osseointegration and vertical augmentation of the alveolar ridge, the higher concentration/dose associated with some local side effects.

• 出版日期2010-6